Biotron Ltd is a biotechnology company focused on the research, development, and commercialization of novel small molecule drugs targeting significant viral diseases. Founded in 1999 and headquartered in Sydney, Australia, Biotron’s primary mission is to address unmet medical needs in the field of antiviral therapeutics. Its leading investigational compound, BIT225, is being developed for the treatment of HIV-1, hepatitis C, and SARS-CoV-2 (COVID-19), and has progressed to Phase II clinical trials. Serving exclusively the healthcare sector, Biotron operates as a clinical-stage entity, driving intermediate and applied biotechnology projects from laboratory research through early-stage clinical testing. With a focused portfolio, Biotron plays a niche but vital role in the pharmaceuticals and biotech sector by aiming to advance therapies that can improve outcomes for patients suffering from viral infections. The company’s activities provide critical R&D momentum in Australia’s biotechnology landscape, supporting innovation in antiviral drug development and contributing to the broader fight against global viral diseases.